| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
As a linker, Ald-Ph-PEG4-acid does not have a traditional biological target. Its role is to connect two functional molecules. In PROTACs, it links an E3 ligase ligand to a target protein binder; in ADCs, it connects an antibody to a drug payload. The aldehyde can react with N-terminal amines or hydrazides, while the acid can be activated to an NHS ester for coupling to amines.
|
|---|---|
| ln Vitro |
In vitro, Ald-Ph-PEG4-acid is used to synthesize bioconjugates. Its utility is demonstrated by the successful formation of stable conjugates via reductive amination or amide bond formation. The PEG spacer improves solubility and reduces aggregation of the conjugates. The phenyl ring may provide additional hydrophobicity or rigidity. These properties are characterized by HPLC and mass spectrometry.
|
| ln Vivo |
In vivo applications of Ald-Ph-PEG4-acid are realized through the conjugates it helps construct. The PEG4 linker contributes to the conjugate's pharmacokinetic properties by increasing hydrodynamic volume and reducing renal clearance. The aldehyde moiety can be used for reversible conjugation, which may be useful for targeted drug release. The compound is a research tool.
|
| Enzyme Assay |
In vitro assays for Ald-Ph-PEG4-acid typically involve demonstrating its reactivity. Reductive amination with a model amine compound can be monitored by HPLC or NMR. Amide bond formation with a primary amine after NHS activation can also be verified. These protocols are for research purposes.
|
| Cell Assay |
In vitro cell-based assays are not performed with the linker alone; they are performed on the final conjugate. For PROTACs, target degradation is assessed by Western blot. For ADCs, cytotoxicity is measured in target-expressing cell lines. The linker's contribution to solubility and cellular uptake can be inferred from comparative studies.
|
| Animal Protocol |
In vivo animal studies are conducted with the final conjugate. Typical protocols involve xenograft tumor models for ADCs or PROTACs. The conjugate is administered intravenously, and tumor growth inhibition is assessed. Pharmacokinetic studies evaluate the half-life and distribution of the conjugate, which are influenced by the linker's properties.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Ald-Ph-PEG4-acid are not independently characterized. The PEG4 spacer provides moderate hydrophilicity. The compound is stored as a powder at -20°C. It is soluble in DMSO and water.
|
| Toxicity/Toxicokinetics |
The toxicity profile of the linker itself is considered low, as PEGylated linkers are generally biocompatible. The toxicity of the final conjugate depends on the payload. Standard safety precautions for handling chemicals apply.
|
| Additional Infomation |
Additional information: Ald-Ph-PEG4-acid contains a benzaldehyde group. It is a heterobifunctional PEG linker for bioconjugation. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C19H27NO8
|
|---|---|
| Molecular Weight |
397.4196
|
| Exact Mass |
397.173
|
| CAS # |
1309460-27-2
|
| PubChem CID |
53486138
|
| Appearance |
Off-white to light yellow viscous liquid
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
28
|
| Complexity |
438
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C=O)C(=O)NCCOCCOCCOCCOCCC(=O)O
|
| InChi Key |
BRYBRKJZWQVXNZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H27NO8/c21-15-16-1-3-17(4-2-16)19(24)20-6-8-26-10-12-28-14-13-27-11-9-25-7-5-18(22)23/h1-4,15H,5-14H2,(H,20,24)(H,22,23)
|
| Chemical Name |
3-[2-[2-[2-[2-[(4-formylbenzoyl)amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5162 mL | 12.5811 mL | 25.1623 mL | |
| 5 mM | 0.5032 mL | 2.5162 mL | 5.0325 mL | |
| 10 mM | 0.2516 mL | 1.2581 mL | 2.5162 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
